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Abstract
After activation CD4+ helper T cells differentiate into T-helper (Th)1 or Th2 effector cells. These
two subsets are characterized by their distinct cytokine expression pattern and the immune
function they mediate. Over the past years, a number of factors have been identified to affect
helper T cell lineage determination, including antigen receptor, coreceptors and, most
importantly, cytokine environment. In this review, we also summarize recent advancement in
understanding of transcriptional and signaling regulation of the differentiation process. This
knowledge will become important in the future to develop means in treating immune disorders.
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AP1 = activating protein 1; APC = antigen-presenting cell; ATF = activating transcription factor; CTLA = cytotoxic T-lymphocyte-associated
antigen; ERK = extracellular-signal-regulated kinase; ICOS = inducible co-stimulator; IkB = inhibitor of NF-kB; IRF = interferon responsive factor;
JNK = c-jun amino-terminal kinase; MAPK = mitogen-activated protein   kinase; MEK = MAPK/ERK kinase; MHC = major histocompatibility
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Introduction
CD4+ Th cells play a central regulatory role in immune and
autoimmune responses. Like CD8+ cytotoxic T cells, Th
cells develop in the thymus, with specificity to recognize
specific major histocompatibility (MHC)–peptide com-
plexes on antigen-presenting cells (APCs). After the
receipt of signals through the T-cell receptor (TCR) and
CD28 costimulator, these cells are triggered to produce IL-
2 and enter the cell cycle. After several days of rapid cell
division, these T cells differentiate into effector cells. During
this process of differentiation, a new pattern of cytokine
expression is established that provides the gene products
that are responsible for the specific effector functions of
these cells, and therefore their ability to protect the host
from a variety of pathogens. Effector CD4+ T cells differ
from their naïve precursors in several characteristics. In
addition to their distinct cytokine expression profiles, naïve
CD4+ T cells require a costimulatory signal for effective
activation, whereas effector T cells are less dependent on
this signal [1]. Moreover, the life-spans of naïve, effector,
and memory T cells are different [2,3].
After more than a decade of research, two classes of
effector CD4+ T cells have been defined on the basis of
the cytokines that they secrete, and the immunomodula-
tory effects conferred by these cytokines [4] (Fig. 1).
Effector Th1 cells produce proinflammatory cytokines
such as IFN-g and lymphotoxin-a. These cytokines orga-
nize inflammatory centers and enhance cellular immune
response; moreover, intracellular pathogens such as
Mycobacteria and  Salmonella spp, and other intravesicu-
lar agents are killed by IFN-g through the activation of
antimicrobial defenses. Th1 cytokine production is also
characteristic of many organ-specific autoimmune dis-
eases, including rheumatoid arthritis, insulin-dependent
diabetes mellitus, experimental autoimmune encephalitis,Arthritis Research    Vol 2 No 3 Dong and Flavell
and others. Effector Th2 cells, in contrast, produce a dif-
ferent profile of cytokines (IL-4, IL-5, IL-9, IL-10, IL-13, and
so on) that together instruct B cells to proliferate and dif-
ferentiate into antibody-secreting plasma cells, and poten-
tiate the function of several cell types in antiparasite
responses. As such, Th2 cells play an important role in
providing protection against certain extracellular
pathogens, such as bacteria and a variety of parasites,
and are also involved in asthmatic reactions.
Proper differentiation of naïve Th cells into Th1 or Th2
cells is critical for a T-dependent immune response. Leish-
mania major infection in mice represents one of best-
studied animal models for Th differentiation and function.
Most common inbred strains can mount a Th1 response
and resolve the lesions; Balb/c mice, however, develop a
Th2 reaction that never heals and renders them suscepti-
ble to the infection [5]. On the other hand, immunodevia-
tion of Th1 responses to the Th2 direction has been
proposed as a means to alleviate the symptoms in auto-
immune diseases.
Because Th1 and Th2 cells are crucial regulators of
immune responses, the mechanisms involved in the differ-
entiation of naïve CD4+ T cells into effector Th1 or Th2
cells have been intensively studied by a number of investi-
gators. A variety of factors have been identified to influence
differentiation along these pathways, including antigen
dose and costimulation (Fig. 1) [6–8]. It is generally
agreed, however, that the most effective inducer of such
differentiation is the cytokine environment. IL-4, in conjunc-
tion with antigenic and costimulatory signals, causes naïve
T cells to differentiate into Th2 effector cells [9,10],
whereas IL-12 drives naïve T cells to differentiate into Th1
cells [11,12]. IL-13, another Th2 cytokine that can bind to
IL-4 receptor a-chain, plays an indispensable role in effi-
cient Th2 cell differentiation [13]. Moreover, we showed
previously [14] that IL-6 derived from APCs is able to
polarize naïve CD4+ T cells into Th2 cells, by potentiating
the initial production of IL-4 by recently activated CD4+
T cells. Recently, IL-18 has been shown [15] to synergize
with IL-12 to potentiate further Th1 responses.
In the present review recent progress in studies of Th cell
lineage commitment and cytokine production is reviewed,
especially that achieved using genetically manipulated
mouse models. In the space available, it was not possible
to cover this entire field. Rather, a number of issues are
the focus.
T-cell receptor and costimulation regulation
T-cell receptor
Th-cell activation and differentiation require interactions of
TCR with MHC classII with specific peptides. The
strength of this interaction influences the outcome of
Th-cell differentiation. In vitro studies using altered
peptide ligands [8], in which activated T cells are the only
source of IL-4, showed that high-affinity binding of peptide
by TCR resulted in Th1 differentiation, whereas lower
affinity binding resulted in Th2 differentiation. Low-affinity
altered peptide ligand stimulation is characterized by failure
to induce full pattern of early tyrosine phosphorylation of
Figure 1
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TCR-associated components and a sustained calcium
mobilization [16], and Th2 differentiation induced under
this condition appeared to depend on IL-4 production by
activated T cells [17]. Similarly, antigen dose could influ-
ence Th-cell differentiation [8]. In addition, Lezzi et al [18]
recently showed that the duration of TCR triggering is dif-
ferentially required for Th1 and Th2 development. Th1
could be achieved by a short TCR stimulation in the pres-
ence of IL-12, whereas Th2 polarization required pro-
longed TCR triggering.
CD4
In addition to TCR, a whole set of cell-surface receptors
are also engaged by their ligands on APCs, which regulate
the Th differentiation program. The CD4 coreceptor binds
to class II MHC, and has been shown to signal through lck.
Leitenberg et al [19] recently found that naïve Th cells that
lack CD4 are defective in Th2 differentiation. Consistent
with this, lck-deficient CD4+ T cells also showed impaired
Th2 development in vitro [20]. Furthermore, itk, which can
be phosphorylated and activated by lck, has recently been
shown to be essential for Th2 development [21].
CD28/cytotoxic T-lymphocyte associated antigen-4 family
CD28 is the most notable costimulatory receptor on
T cells, which binds to B7.1 (CD80) or B7.2 (CD86) on
activated APCs. MHC–TCR–CD4 interaction provides a
first signal for T-cell activation, and B7–CD28 interaction
provides the second. In Th1 clones, both signals are
required for IL-2 production and cell proliferation [22].
Giving signal one in the absence of signal two rendered
the Th1 clones anergized or unresponsive. In support of
an essential role of B7–CD28 interaction in primary T-cell
activation, studies using T cells derived from CD28-defi-
cient mice [23] demonstrated its role in T-cell proliferation
and survival. In addition, several lines of evidence indicate
that the CD28 signal is crucial for Th2 differentiation.
Seder  et al [24] showed that no IL-4 was produced when
the CD28–B7 interaction was blocked with hCTLA-4-Ig.
We also observed that CD4+ T cells required CD28 cos-
timulation for IL-4, IL-5, and IL-10 production, whereas in
its absence only IFN-g was produced [25]. A study using
an APC that was deficient for both B7.1 and B7.2 mole-
cules [26] also demonstrated that IL-4 production and
Th2 differentiation is highly dependent on B7, whereas for
Th1 cells only IL-2 is sensitive to B7 regulation [27]. In
vivo, CD28–/– mice have a reduced Th2-dependent anti-
body response to vesicular stomatitis virus, whereas the
Th1-dependent delayed-type hypersensitivity response to
lymphocytic choriomeningitis virus remains intact [28,29].
In addition, blockade of B7–CD28 interaction in vivo
reduced the Th2 responses in both Leishmania and nema-
tode infection models [30].
The molecular mechanism by which CD28 mediates Th2
differentiation is not very clear. One possibility is that CD28
amplifies TCR signals for Th2 induction. In support of this,
Viola et al [31] observed that CD28 cosimulation resulted in
reorganization of membrane lipid microdomains and sus-
tained tyrosine phosphorylation. Consistent with this, we
showed [25] that CD28 enhanced nuclear accumulation of
nuclear factor of activated T cells (NFATc), a transcription
factor required for Th2 differentiation. Alternatively, CD28
enhancement of cell proliferation may favor Th2 differentia-
tion, because Bird et al [31] discovered that IL-4 expression
requires more cell divisions than does expression of IFN-g.
CTLA-4 is a homolog of CD28 that is strongly induced on
activated T cells, which has a 10-fold higher affinity for B7
binding than does CD28 [32]. CTLA-4 plays an inhibitory
costimulatory role in regulating T-cell response. Mice that
are deficient in CTLA-4 display polyclonal T-cell activation
and a lymphoproliferative disorder that resulted in neonatal
lethality [32]. Recently, Khattri et al [33] found that
CTLA-4-deficient T cells secrete high levels of IL-4 and
IL-5, indicating that CTLA-4 functions to downregulate the
CD28 signal in Th2 induction.
A third CD28 homologous molecule, inducible costimula-
tor (ICOS), was identified just last year [34]. It is also
expressed by activated T cells. It may not bind to B7
because, unlike CD28 or CTLA-4, it does not possess the
MYPPPY motif in its immunoglobuln domain. ICOS cos-
timulation enhances T-cell proliferation and cytokine pro-
duction. Most notably, it is more potent in IL-10 induction
than is CD28, suggesting that it can potentially regulate
Th-cell development, especially at a stage where CD28
signal is downregulated by B7–CTLA-4 engagement. To
add further complexity, two more B7 homologs were
recently reported. One of them, B7h/B7-RP1 that is
induced by the inflammatory cytokine tumor necrosis
factor (TNF)-a was shown to bind to ICOS, whereas the
other one, B7h1, could not [35–38]. Whether B7h/B7-
RP1 is the only ligand for ICOS and what is the receptor
for B7h1 requires further investigation.
Tumor necrosis factor receptor family
Several members of the TNF receptor/ligand families have
been suggested to play a role in T-cell costimulation and dif-
ferentiation. CD40 ligand (CD154), which is expressed by
activated T cells, is crucial for T-cell-mediated immune
response [39]. Its binding of CD40 on APCs results in their
expression of the inflammatory cytokine IL-12 and of costim-
ulatory factors. Recently, TNF-related activation-induced
cytokine (TRANCE)/TRANCE receptor, another TNF–TNF
receptor pairing, has been shown to function independently
of CD40/CD40 ligand to mediate IL-12 production by den-
dritic cells in vitro and IFN-g response during a viral infection
in vivo [40,41]. OX40, which is also expressed by activated
T cells, plays an important role in Th1-type immune
responses. In mice lacking OX40, there was reduced
number of IFN-g-producing CD4+ T cells in response to viralinfection [42]. On the other hand, mice deficient in OX40
ligand exhibited impaired delayed hypersensitivity [43].
IL-12 transcription in APCs and the IL-12-
dependent T-cell response
IL-12, a heterodimeric cytokine that consists of p35 and
p40 subunits, plays a central role in driving naïve CD4+
T cells to differentiate into Th1 effector cells. IL-12
p40-deficient mice, IL-12 receptor b1-deficient mice and
mice deficient for signal transducer and activator of tran-
scription (Stat)4, a key signaling molecule that is required
in order to respond to IL-12, all exhibited defective type I
cytokine immuneresponses [44–47].
In comparison with the IL-12 p35 promoter, the IL-12 p40
promoter and the transcription factors that bind to it are
better characterized. CATA enhancer binding protein and
nuclear factor-kB (NF-kB) family members, together with
an ets-2-related factor, have been shown to bind to their
corresponding sites in the p40 promoter and to regulate
the expression of this gene [48–52]. By the use of gene
disruptions in mice, interferon responsive factor (IRF)-1
and interferon consensus sequence binding protein
(another member of the IRF-1 family) have been shown to
be required forIL-12 p40 expression [53–56].
IL-12 is secreted mainly by APCs upon innate immune
recognition of pathogen-associated molecular patterns,
including lipopolysaccharide. Lipopolysaccharide has
recently been determined to function through Toll-like
receptors [57]. In addition, as stated above, IL-12 expres-
sion can also be regulated by signals from members of the
TNF receptor family, including CD40 and TRANCE recep-
tor. How signals from these receptors activate IL-12 tran-
scription machinery is not yet completely understood. Our
laboratory has recently found that p38 mitogen-activated
protein kinase (MAPK) pathway, activated by lipopolysac-
charide or CD40, plays a crucial role in IL-12 regulation
[58]. Macrophages isolated from mice deficient in the p38
kinase, MAPK kinase (MKK)3, have a profound defect in
IL-12 p35 and p40 transcription when stimulated by
lipopolysaccharide. Furthermore, Mkk3–/– dendritic cells
failed to express IL-12 in response to CD40 activation. In
a mouse macrophage cell line, activation of the p38
pathway activates IL-12 p40 promoter activity. These
results demonstrate that p38 MAPK is necessary and suf-
ficient to mediate IL-12 expression.
IL-12 receptor expression by T cells is regulated during Th
differentiation, which may impact on their responsiveness to
IL-12 and resultant lineage determination. Szabo et al [59]
showed that IL-12 receptor b2 subunit, which is not
expressed in naïve T cells, is induced by TCR ligation. IL-4
inhibits its expression, which may lead the cells to become
unresponsive to IL-12 and differentiate into the Th2 subsets.
On the other hand, IFN-g overcomes this inhibition.
Interleukin-4 transcription regulation
IL-4 is a cytokine that is not only produced by differentiat-
ing and differentiated Th2 cells, but also is the key factor
driving Th2 differentiation. The source of the initial IL-4
that primed the Th2-type response in vivo has been
debated for some years. Natural killer T cells produce IL-4
very rapidly upon TCR engagement and were therefore
thought to be the regulatory cell for Th2 reaction. Mice
that are deficient for CD1, and thus for natural killer
T cells, have normal Th2 responses, however, which sug-
gests that IL-4 may come from other sources [60,61].
Balb/c mice, during Leishmania major challenge, devel-
oped a Th2-polarized response [62]. In these mice, during
the early phase of infection a subset of T cells bearing
Vb4+Va8+ TCR that recognizes Leishmania antigen
secrete IL-4 and may be responsible for the Th2 skewing
in vivo [62]. Whether this is a regulatory cell or simply an
antigen-specific CD4+ T cell remains to be determined.
Recently, two reports [63,64] demonstrated that IL-4 is
expressed in a monoallelic manner. Bix and Locksley [64]
established Th2 cell clones from Balb/c X CaST/Ei F1
mice and analyzed the allelic expression of the IL-4 gene.
They found that most clones were expressed in a mono-
allelic manner and that the allelic pattern was transmitted
as a stable epigenetic trait. In anther study, Riviere et al
[63] generated a mouse strain in which one allele of the
IL-4 gene was replaced by human CD2 by gene targeting.
Using this model, they convincingly showed that most Th2
cells expressed only the functional IL-4 allele or the tar-
geted allele. Estimation of the frequency of monoallelic
versus biallelic expression in this model also suggests a
stochastic process in the activation of each individual
allele, in which each cytokine gene can be turned on prob-
abilistically to generate diverse profiles of cytokine expres-
sion and effector population.
The IL-4 gene is located on chromosome 11 in a locus
containing the gene for the other Th2 cytokines IL-5 and
IL-13, which suggests a mechanism to coordinate the
expression of these genes. Two groups have identified
several deoxyribonuclease I-hypersensitivity sites in IL-4
and IL-13 gene loci that are associated with Th2 differenti-
ation [65,66], which may indicate a chromatin remodeling
process during Th2 commitment that makes the loci more
accessible to the transcription machinery. In addition, IL-4
locus remodeling is accompanied by demethylation and
was shown to require both antigen receptor and IL-4
cytokine signaling [66]. However, the functional signifi-
cance of these hypersensitive sites, and whether they are
enhancers for transcription factor binding or one or more
of them constitute a locus-control region, as reported for
b-globin [67] and CD2 loci [68], are still unclear.
The 800-bp proximal promoter of the IL-4 gene has been
extensively studied, and it confers Th2 specificity in
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level than the endogenous gene [69]. Furthermore, the
NFAT–activating protein 1 (AP1) composite element in
this region, when placed in an IL-4 or IL-2 minimal pro-
moter, is expressed with Th2 specificity, indicating a role
for the NFAT and AP1 transcription factor families in regu-
lation of IL-4 gene expression [69–71].
Nuclear factor of activated T cells
Thus far five NFAT members have been identified – NFATp
(NFAT1 or c2), NFATc (NFAT2 or c1), NFAT3 (NFATc4),
NFAT4 (NFATc3 or x), and NFAT5 – all of which contain a
rel homology domain that is responsible for DNA binding
[72]. The first four NFATs are cytoplasmic and translocated
into the nucleus only after dephosphorylation in their
serine-proline rich and serine rich regions by calcineurin
phosphatase [72]; NFAT5 is constitutively nuclear [73].
Unlike NF-kB proteins, NFATs bind to DNA in a complex
with other factors, including AP-1 molecules [72,74]. In
fact, NFAT–AP1 composite sequences exist in promoters
of numerous cytokine and immune effector genes, and
have been shown to be critical for regulation of these
genes. Deletion or mutation of NFAT sites in the IL-4 pro-
moter abolished its transcription activity [75]. NFATc and
NFATp have been shown [74,76] to bind to the
NFAT–AP1 site in the IL-4 promoter and to activate IL-4
transcription in cell lines. Analysis of knockout mice for
these two genes distinguished their potential roles in IL-4
regulation, however. In mice that are deficient for NFATp or
for both NFATp and NFAT4, there is an exaggerated Th2
response [77–79]. In contrast, NFATc knockout mice dis-
played defective Th2 differentiation [80,81]. Thus, NFATp
and NFATc seem to play opposite regulatory roles in IL-4
regulation. Precisely why this is so is still a puzzle.
GATA-3
Using the representation difference analysis approach, we
found GATA-3 to be selectively expressed in the Th2
pathway [82]. Existing in naïve CD4+ T cells and shortly
after activation, GATA-3 mRNA and IL-4 gene expression
are extinguished in Th1 cells, whereas GATA-3 levels are
elevated in Th2 cells. Interestingly, through analysis of IL-5
promoter, Zhang et al [83] also identified GATA-3 as a
Th2-specific factor. In addition, Ouyang et al [84] found
that diminished GATA-3 expression in Th1 differentiation
is dependent on IL-12. During the past 2 years, GATA-3
has been shown by several studies to be the critical regu-
latory transcription factor involved in Th2 differentiation.
We showed [82] that T cells isolated from transgenic
mice in which GATA-3 was forced to be overexpressed
produced IL-4, IL5, IL-6, and IL-10 mRNA, even when they
developed under Th1 conditions in the complete absence
of exogenous IL-4. Zhang et al [83] also found that GATA-
3 could activate the IL-5 promoter in vitro. Moreover,
GATA-3 was also reported to inhibit T-cell responsiveness
to IL-12 in IFN-g [84]. On the other hand, reduction of
GATA-3 function in cloned Th2 cells by antisense led to
the extinction of IL-4, IL-5, IL-6, IL-10, and IL-13 Th2
cytokine gene mRNA expression and protein secretion
[82]. This result was confirmed by a more recent study
[85], in which expression of a dominant-negative mutant of
GATA-3 in mice in a T-cell-specific manner reduced the
expression of all of the Th2 cytokines IL-4, IL-5, and IL-13,
and diminished airway hypersensitivity in vivo. Finally, Arai
et al [86] recently showed that retrovirally expressed
GATA-3 could cause fully committed Th1 cloned T cells to
produce IL-4 and IL-5. In another study, Ouyang et al [87],
using a similar approach, found that GATA-3 expression
could rescue Th2 development in Stat6-deficient cells,
resulting in Th2 cytokine expression and the establishment
of Th2-specific deoxyribonuclease I hypersensitive sites in
the IL-4 locus. These experiments show that GATA-3 is
the master Th2 regulatory factor, and is both necessary
and sufficient to generate Th2 responses. How GATA-3
works is still not understood, however. The proximal pro-
moter of IL-4 gene lacks a strongly functional GATA-3-
binding site, so we believe that its major role is likely to be
as a Th2-specific enhancer(s) or perhaps as a locus
control region (eg in the IL-4, IL-5, and IL-13 regions).
c-Maf
c-Maf is a basic region/leucine zipper transcription factor
that is not expressed by naïve cells, and is induced when
cells differentiate into the Th2 lineage [88]. It binds to a
site in the proximal IL-4 promoter. Overexpression of c-maf
strongly induced IL-4 expression in non-T cells. Trans-
genic mice in which c-maf overexpression was driven by
the CD4 promoter exhibited enhanced Th2 responses that
were dependent on IL-4 [89]. Decreased IFN-g production
seen in these mice is not dependent on IL-4. Unlike,
GATA-3, however, c-maf does not appear to act by itself,
as c-maf-overexpressing Th cells failed to express IL-4
under Th1-skewing conditions [89]. The importance of
c-maf in IL-4 expression is further strengthened by a report
that c-maf–/– Th and natural killer T cells are defective in
IL-4 production [90]. Th2 differentiation and cytokine pro-
duction appear normal in the absence of c-maf, however,
which is probably due to a compensatory role by IL-13
that is normally expressed. Thus, c-maf is a transcription
factor that plays an important role in IL-4, but not of other
cytokine gene expression.
JunB
JunB, a member of the c-jun family of transcription factors,
was found to be selectively expressed in Th2 cells
[70,91]. JunB binds specifically to the AP-1 site of the P1
element, and when junB was overexpressed in transgenic
mice it caused developing Th1 cells to overproduce IL-4
and IL-5, and to a lesser extent IL-6 and IL-10, which are all
Th2 products [91]. The mechanism whereby JunB achieved
this overexpression was through synergy with c-maf [91].
JunB and c-maf synergized in transient transfection studies
http://arthritis-research.com/content/2/3/179using reporters for the promoter proximal element of the
IL-4 promoter. This synergy was specific for JunB,
because neither c-jun or JunD is capable of synergizing.
Interestingly, to perform this function JunB required phos-
phorylation at two threonine residues (102 and 104) by c-
jun amino-terminal kinase (JNK), and mediated c-maf
binding to DNA in a phosphorylation-dependent manner.
Paradoxically, although it has previously been considered
to be a transcriptional repressor, JunB activates transcrip-
tion in the context of IL-4 promoter.
Signaling pathways that mediate T-helper-cell
differentiation
Janus kinase (JAK)–signal transducer and activator of
transcription (STAT) pathways
First identified as downstream of IFN signaling, the
JAK–STAT pathway has been demonstrated to be essen-
tial for cytokine regulation of cell growth and differentia-
tion. In general, cytokine-induced receptor dimerization
activates JAK kinases, which then phosphorylate and initi-
ate the nuclear transport of STAT transcription factors.
STAT4 is activated by IL-12, and STAT4-deficient mice
exhibited a profound Th1 defect [45,46]. On the other
hand, STAT6, which acts downstream of IL-4, is required
for Th2 differentiation [92–94]. Bcl-6 was reported to
compete with STAT6 for the same binding site, and thus
was considered as a negative regulator of Th2 responses
[95]. In support of this, Bcl-6 knockout mice exhibited
autoimmune diseases that were characterized as Th2 type
[95]. Although STAT function in Th-cell differentiation has
been well established, their immediate downstream target
gene(s) remain unknown. For instance, the proximal IL-4
promoter lacks a STAT site. There is a report [96] that
STAT6 may bind to a site in an intronic repressor and
released the inhibition. Whether this is the exact physio-
logical function for STAT6 remains to be determined.
Alternatively, STAT6 may function to regulate expression
of other transcription factors that are involved in Th2 differ-
entiation, and attractive candidate genes are GATA-3 and
c-maf. Indeed, Kurata et al [97] found that retroviral
expression of STAT6 can result in GATA-3 and c-maf
expression and Th2 cytokine production in cells differenti-
ated into the Th1 lineage.
Extracellular-signal-regulated kinase (ERK)–mitogen-
activated protein kinase pathway 
There are three major MAPK pathway in mammals: ERK,
p38 and JNK [98]. Each pathway consists of three
cascades of activation events (i.e. MAPK kinase kinases
phosphorylate MAPK kinases, which then activate MAPKs).
The ERK pathway was first identified downstream of onco-
genic Ras, and is often involved in the regulation of cell
growth and differentiation. There are two isoforms of ERK,
ERK1 and ERK2, which are sometimes referred to as
p44/p42 MAPKs. They can be activated by MAPK/ERK
kinase (MEK)1 and 2 upstream kinases. The RAS–ERK
pathway plays an important role in early thymocyte differ-
entiation and selection, and its role in peripheral Th-cell
differentiation was not studied until recently. Yamashita et
al [99], using dominant H-RAS transgenic mice in which
ERK activation by TCR was severely compromised,
showed that this pathway is required for Th2-cell differen-
tiation [99]. Similar results were found using wild-type
cells treated with inhibitors against MEKs. Those investi-
gators went further to show that the ERK pathway func-
tions to enhance IL-4-induced STAT6 and IL-4 receptor
phosphorylation, which suggests a mechanism of cross-
regulation among different signaling pathways.
P38–mitogen-activated protein kinase pathway
The p38 and JNK protein kinases are also members of the
MAPK family that are activated in response to stress and
inflammatory cytokines. These enzymes are also activated
by MKKs, specifically MKK3 and MKK6 in the case of p38
[99]. The p38 MAPKs comprise members of a parallel
stress-activated MAPK pathway. Here, too, there are multi-
ple isoforms and p38 is found as four enzymes: p38-a,
p38-b, p38-g, and p38-d.
The p38–MAPK pathway is selectively activated in mouse
Th1 effector cells [100]. Imidazole inhibitors of the p38
kinases block IFN-g production by Th1 cells in a dose-
dependent manner, but have no effect on IL-4 production
by Th2 cells. Furthermore, transgenic mice in which a
dominant-negative p38-a transgene was directed by the
LCK distal promoter showed reduced IFN-g cytokine
secretion and mRNA production [100]. T cells from mice
deficient in the p38 upstream kinase MKK3 have an intrin-
sic defect to produce normal levels of IFN-g, even when
provided with APCs from a wild-type B6 mouse [58]. The
effect of the p38 pathway on IFN-g is probably transcrip-
tional, because IFN-g reporters are also inhibited by domi-
nant-negative p38-a construct in Jurkat cells, indicating
that p38 regulation is necessary for IFN-g expression. On
the other hand, transgene-encoded constitutively active
MKK6, one of the upstream MKKs that activates p38
kinase, led to the predicted opposite result, namely the
activation of p38 MAPK and the consequent activation of
IFN-g transcription to higher levels than those seen in
control transgene negative cells [100].
Candidate downstream targets of p38 regulation are likely
to include transcription factors of the activating transcrip-
tion factor (ATF) family. Studies of the IFN-g promoter, the
prototype Th1-specific cytokine, led to the identification of
c-jun/ATF2 sites and a series of other ATF-binding sites
within two functionally active elements called the proximal
and distal IFN-g elements [101,102]. Transgenic mice in
which these two elements were linked to luciferase
reporter constructs [103,104] showed that the proximal
element that carries a c-jun/ATF2 site exhibited Th1 speci-
ficity, whereas the distal element did not.
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The JNK group of MAPKs are also known as stress-acti-
vated protein kinases, which are activated by exposure of
cells to cytokines and a variety of environmental stresses.
JNK activation is mediated by dual phosphorylation on
threonine and tyrosine residues in a Thr-Pro-Tyr motif by
two MKKs known as MKK4 and MKK7 [105]. MKK4, also
known as SEK1, was initially identified as a component of
the JNK signaling pathway, but it can phosphorylate p38
as well.
JNK phosphorylates c-Jun and increases AP1 transcrip-
tional activity. JNK activation in Jurkat cells has been
shown to require both TCR and CD28 ligation, and JNK is
suggested to integrate signals from both sets of receptors
to induce IL-2 expression [106]. However, induction of
JNK activity in primary mouse T cells is slow and peaks at
approximately 2–3 days after T-cell activation, during
which time there is substantial de novo synthesis of JNK
protein [107]. Thus, there is an apparent paradox with
regard to the timing of IL-2 gene expression, which occurs
within several hours of T-cell activation, at a time when
there is little JNK activity. JNK activity does, however, cor-
relate well with the expression of effector cytokines in both
the Th1 and Th2 pathways. Indeed, knockout mice for
either  Jnk1 or  Jnk2 genes exhibited defective phenotypes
associated not with Th-cell activation, but with Th-cell dif-
ferentiation. Mice that are deficient in JNK2 show deficient
Th1 immune responses [108]. Reduced levels of IFN-g are
found and this appears to derive from a reduced produc-
tion of the IL-12 receptor b2-chain. This deficiency itself is
a consequence of the failure to produce optimal levels of
IFN-g early during the response to T-cell receptor and cos-
timulator ligation. Addition of IFN-g to JNK2-deficient
T cells restores the deficit and confers normal Th1 func-
tion on these cells in vitro. In contrast, the Th2 responses
of JNK2-deficient mice appear relatively normal.
JNK1-deficient mice, in contrast, show an exaggerated
Th2 response [25]. Even when cultured under Th1 condi-
tions, the Th2 cytokines IL-4, IL-5, and IL-10 are produced
in significant amounts. Consistent with this exaggerated
Th2 response, infection of JNK1 mice with Leishmania
leads to greatly exacerbated disease with failure to heal
skin lesions; the disease advances to ulceration in a
manner similar to that in the BALBc mouse, which also
has a profoundly strong Th2 response [Constant et al,
unpublished data]. Th2 responses themselves are exag-
gerated and JNK1 mice that are immunized with protein
antigens develop enhanced Th2-cell responses in recall
assays in vitro [25]. Most notably, Jnk1–/– T cells pro-
duced Th2 cytokines in the absence of CD28 costimula-
tion and differentiate preferentially into Th2 cells in vitro
when stimulated with anti-CD3, irradiated APCs, and IL-2,
whereas the wild-type became mostly Th1 cells [25]. This
is probably caused by enhanced IL-4 production at the
early phase (ie 24-h and 48-h time point) of Th-cell activa-
tion. Examination of Th2 transcription factors expression at
this stage shows that JNK1-deficient mice have elevated
NFATc in the nucleus [25]. Because NFATc-deficient
mice have reduced IL-4 production and NFAT itself can
efficiently transactivate the IL-4 promoter, we believe that
this elevated NFAT leads to exaggerated production of
Th2 cytokines. It is likely, therefore, that JNK1 plays a role
in negatively regulating the level of NFATc in the nucleus.
The mechanisms that underlie this process are under
further investigation.
I-k kB kinase-nuclear factor-k kB pathway
NF-kB proteins normally exist in the cytoplasm associated
with inhibitor of NF-kB (I-kB) molecules. Upon activation
by upstream kinases, NF-kB-inducing kinase or MEK
kinase 1 for instance, I-kB kinases are activated and phos-
phorylate I-kB proteins, which leads to their dissociation
from NF-kB and degradation by ubiquination-dependent
proteosomes, and NF-kB proteins translocate into the
nucleus to trans-activate target genes. NF-kB factors are
known for their essential roles in innate immune responses
(ie production of inflammation cytokines and B7 mole-
cules). Their roles in Th cell differentiation have just begun
to receive attention and appreciation. Using transgenic
mice expressing a I-kB mutant that can not be phosphory-
lated, thereby inhibiting NF-kB nuclear transport, Aronica
et al [110] recently demonstrated that the NF-kB pathway
is required for Th1-dependent delayed-type hypersensitiv-
ity responses, but not for a Th2-characterized airway
hypersensitivity response. The molecular mechanism for
this observation and the downstream gene(s) mediated by
NF-kB certainly require further investigation.
Conclusion
Recent years have seen rapid progress in study of Th-cell
differentiation. Th1/Th2 lineage determination is mediated
by TCR, coreceptors and, most importantly, the cytokine
environment (Fig. 1). A number of signaling pathways pos-
itively or negatively regulate the transcription factors that
are responsible for polarized cytokine production (Fig. 1).
An in-depth understanding of these events is likely to be
achieved in the coming years, and the complexity of the
differentiation program will be further appreciated with
realization of exquisite regulation and cross-regulation of
each pathway and factor. We believe that improvement of
our knowledge in the field will greatly benefit development
of efficient pharmacologic means for treating immune dis-
orders that are suffered by millions of people today.
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